Kymera Therapeutics price target raised to $119 from $70 at Barclays

Barclays raised the firm’s price target on Kymera Therapeutics (KYMR) to $119 from $70 and keeps an Overweight rating on the shares. The firm updated the company’s model following the Phase 1b BroADen update. The data “significantly de-risks” KT-621’s potential in T helper 2 cells driven disease, the analyst tells investors in a research note. Barclays sees share upside if KT-621 can achieve “Dupi-like sales.”